← Back to Search

CBT + HIV Risk Reduction for Social Anxiety (SC-RCT Trial)

N/A
Recruiting
Led By Trevor A Hart, Ph.D, CPsych
Research Sponsored by Ryerson University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Participants must self-identify as a man (including trans* men who self-identify as men) and be aged 18 or older
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, 14 weeks, 3- and 6- month follow-up
Awards & highlights

SC-RCT Trial Summary

This trial will provide the first efficacy data for a novel and innovative HIV prevention intervention for MSM that combines the most empirically supported treatment for social anxiety disorder, cognitive-behavioural therapy, with HIV risk reduction counselling.

Who is the study for?
This trial is for HIV-negative gay, bisexual, and other men who have sex with men (MSM) over 18 years old. Participants must experience social anxiety, engage in condomless anal sex without PrEP with partners of unknown or positive HIV status, and use substances before or during sexual activity.Check my eligibility
What is being tested?
The study tests a new intervention combining cognitive-behavioural therapy (CBT) with HIV risk reduction counselling against applied relaxation to treat social anxiety disorder and reduce substance use and HIV risk behaviors in MSM.See study design
What are the potential side effects?
While not explicitly listed, side effects may include discomfort from discussing personal issues during CBT sessions or relaxation exercises. There could also be emotional distress related to confronting anxiety-provoking situations.

SC-RCT Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am a man aged 18 or older.

SC-RCT Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, 14 weeks, 3- and 6- month follow-up
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, 14 weeks, 3- and 6- month follow-up for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Condomless Anal Sex with partners of unknown or HIV-positive status, without participant use of PrEP, based on response at 6 months (yes/no).
Secondary outcome measures
Hepatitis Viruses
Qualitative Exit Interview
Self-report measures
+3 more

SC-RCT Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Cognitive Behavioural TherapyExperimental Treatment1 Intervention
In sessions 1-2, the participant's sexual history and goals regarding social anxiety reduction and HIV risk reduction will be discussed, including reducing CAS, and considering use of PrEP to reduce HIV risk. In sessions 3-4, the role of social anxiety and substances in social avoidance and HIV risk will be discussed, and a fear hierarchy of the participant's social fears will be created. In sessions 5-7, cognitive restructuring and coping skills for anxiety reduction will be discussed. In sessions 8-9, participants will face their fears via exposures to feared situations using their new cognitive coping skills. In sessions 10-11, exposures are continued with a focus on (a) situations higher in the fear hierarchy and (b) the role of substance use as a barrier to personal goals. In session 12, relapse prevention and goals for progress regarding social anxiety, substance use, and HIV risk reduction beyond the end of therapy will be discussed.
Group II: Applied RelaxationActive Control1 Intervention
In AR, patients are trained in progressive muscle relaxation, and then taught to practice using relaxation when facing feared situations, as a new coping response. AR involves noticing early signs of anxiety, learning relaxation skills, and applying relaxation at the first sign of anxiety. This therapy is chosen because it does not involve the cognitive and exposure focused techniques that are used in the experimental condition. Reviews of psychological treatments show that AR does not statistically differ from cognitive restructuring with exposure in its effects on social anxiety. However, AR is an appropriate control arm for the present study because it is credible and can be time-matched to CBT, but has no theoretical or empirical support for substance use management or HIV risk behaviour reduction, the latter of which is the primary outcome of the present study.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Cognitive Behavioural Therapy
2016
Completed Phase 3
~3800

Find a Location

Who is running the clinical trial?

Ryerson UniversityLead Sponsor
76 Previous Clinical Trials
7,723 Total Patients Enrolled
Toronto Metropolitan UniversityLead Sponsor
84 Previous Clinical Trials
10,791 Total Patients Enrolled
University of British ColumbiaOTHER
1,415 Previous Clinical Trials
2,466,840 Total Patients Enrolled

Media Library

Applied Relaxation Clinical Trial Eligibility Overview. Trial Name: NCT04381559 — N/A
Social Anxiety Research Study Groups: Applied Relaxation, Cognitive Behavioural Therapy
Social Anxiety Clinical Trial 2023: Applied Relaxation Highlights & Side Effects. Trial Name: NCT04381559 — N/A
Applied Relaxation 2023 Treatment Timeline for Medical Study. Trial Name: NCT04381559 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is registration currently open for this research?

"Affirmative, according to the information on clinicaltrials.gov this medical study is still in its enrollment phase. The trial first appeared online on December 15th 2020 and was last updated April 25th 2022. 176 patients are needed from 1 participating site for completion of the research project."

Answered by AI

How many individuals are participating in the current clinical experiment?

"Affirmative. Clinicaltrials.gov displays that this clinical trial is actively recruiting participants, with the initial posting on December 15th 2020 and last update on April 25th 2022. The study aims to enroll 176 patients at a single site."

Answered by AI
~4 spots leftby May 2024